A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease (clinicaltrials.gov) - Sep 17, 2026 - P=N/A | N=6700 | Recruiting | Sponsor: Eisai Inc.
New trial • Real-world evidence • Alzheimer's Disease • CNS Disorders
|